메뉴 건너뛰기




Volumn 7, Issue 3, 2014, Pages 397-406

Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Author keywords

BCR ABL1; Chronic myeloid leukemia; Imatinib; Philadelphia (chromosome); Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

EID: 84900839000     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.900432     Document Type: Review
Times cited : (5)

References (87)
  • 1
    • 34447646300 scopus 로고    scopus 로고
    • On behalf of the european leukemianet chronic myeloid leukemia
    • Hehlmann R, Hochhaus A, Baccarani M; on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet 2007;370:342-50
    • (2007) Lancet , vol.370 , pp. 342-350
    • Hehlmann, R.1    Hochhaus, A.2    Baccarani, M.3
  • 2
    • 35448967331 scopus 로고    scopus 로고
    • Part I. Mechanisms of resistance to imatinib in chronic myeloid leukemia
    • Apperley JF, Part I. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007;8:1018-29
    • (2007) Lancet Oncol , vol.8 , pp. 1018-1029
    • Apperley, J.F.1
  • 3
    • 36549088120 scopus 로고    scopus 로고
    • Part II. Management of resistance to imatinib in chronic myeloid leukaemia
    • Apperley JF, Part II. Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-29
    • (2007) Lancet Oncol , vol.8 , pp. 1116-1129
    • Apperley, J.F.1
  • 4
    • 77958012952 scopus 로고    scopus 로고
    • Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
    • Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24(10):1719-24
    • (2010) Leukemia , vol.24 , Issue.10 , pp. 1719-1724
    • Ross, D.M.1    Branford, S.2    Seymour, J.F.3
  • 5
    • 77956545790 scopus 로고    scopus 로고
    • In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
    • Sobrinho-Simoes M, Wilczek V, Score J, et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116(8):1329-35
    • (2010) Blood , vol.116 , Issue.8 , pp. 1329-1335
    • Sobrinho-Simoes, M.1    Wilczek, V.2    Score, J.3
  • 6
    • 80053361301 scopus 로고    scopus 로고
    • Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular resistant disease
    • Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular resistant disease. Blood 2011;118(13):3657-60
    • (2011) Blood , vol.118 , Issue.13 , pp. 3657-3660
    • Chomel, J.C.1    Bonnet, M.L.2    Sorel, N.3
  • 7
    • 81555214617 scopus 로고    scopus 로고
    • Persistence of leukemia stem cells in chronic myelogeneous leukemia patients in prolonged remission with imatinib treatment
    • Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogeneous leukemia patients in prolonged remission with imatinib treatment. Blood 2011;118:5565-72
    • (2011) Blood , vol.118 , pp. 5565-5572
    • Chu, S.1    McDonald, T.2    Lin, A.3
  • 8
    • 33747154547 scopus 로고    scopus 로고
    • Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the european leukemianet
    • Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108: 1809-20
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 9
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: An update of concepts and management recommendations of european leukemianet
    • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3
  • 10
    • 84881298446 scopus 로고    scopus 로고
    • EuroepanLeukemiaNet recommendations for the management of chronic myeloid leukemi
    • Baccarani M, Deininger M, Rosti G, et al. EuroepanLeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013;122(6):872-84
    • (2013) Blood , vol.122 , Issue.6 , pp. 872-884
    • Baccarani, M.1    Deininger, M.2    Rosti, G.3
  • 12
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: The adagio study
    • Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009;113:5401-11
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    Van Lierde, M.A.2    De Bock, R.3
  • 13
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib
    • Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib. J Clin Oncol 2010;28:2381-8
    • (2010) J Clin Oncol , vol.28 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.X.3
  • 14
    • 52649177063 scopus 로고    scopus 로고
    • Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
    • Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-7
    • (2008) Blood , vol.112 , pp. 2024-2027
    • Dulucq, S.1    Bouchet, S.2    Turcq, B.3
  • 15
    • 77954936879 scopus 로고    scopus 로고
    • Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
    • White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-7
    • (2010) J Clin Oncol , vol.28 , pp. 2761-2767
    • White, D.L.1    Dang, P.2    Engler, J.3
  • 16
    • 84875296042 scopus 로고    scopus 로고
    • Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
    • Angelini S, Soverini S, Ravegnini G, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013;98(2):193-200
    • (2013) Haematologica , vol.98 , Issue.2 , pp. 193-200
    • Angelini, S.1    Soverini, S.2    Ravegnini, G.3
  • 17
    • 9444282642 scopus 로고    scopus 로고
    • Active transport of imatinib into and out of cells: Implications for drug resistance
    • Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45
    • (2004) Blood , vol.104 , pp. 3739-3745
    • Thomas, J.1    Wang, L.2    Clark, R.E.3
  • 18
    • 84862777672 scopus 로고    scopus 로고
    • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
    • Ng KP, Hillmer AM, Chuah CTH, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18(4):521-8
    • (2012) Nat Med , vol.18 , Issue.4 , pp. 521-528
    • Ng, K.P.1    Hillmer, A.M.2    Cth, C.3
  • 19
    • 0037443754 scopus 로고    scopus 로고
    • MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
    • Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73
    • (2003) Blood , vol.101 , pp. 2368-2373
    • Mahon, F.X.1    Belloc, F.2    Lagarde, V.3
  • 20
    • 70349254450 scopus 로고    scopus 로고
    • Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    • Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168-71
    • (2009) Blood , vol.114 , pp. 2168-2171
    • Soverini, S.1    Gnani, A.2    Colarossi, S.3
  • 21
    • 80051573352 scopus 로고    scopus 로고
    • BCR-ABL kinase domain mutations analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Recommendations from an expert panel on behalf of european leukemianet
    • Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutations analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118(5):1208-15
    • (2011) Blood , vol.118 , Issue.5 , pp. 1208-1215
    • Soverini, S.1    Hochhaus, A.2    Nicolini, F.E.3
  • 22
    • 84856708602 scopus 로고    scopus 로고
    • Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant patients
    • Gruber FX, Ernst T, Porkka K, et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant patients. Leukemia 2012;26:172-7
    • (2012) Leukemia , Issue.26 , pp. 172-177
    • Gruber, F.X.1    Ernst, T.2    Porkka, K.3
  • 23
    • 84872462658 scopus 로고    scopus 로고
    • BCR-ABL1 compound mutations in tyrosine kinase inhibitor resistant CML: Frequency and clonal relationship
    • Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor resistant CML: frequency and clonal relationship. Blood 2013;121:489-98
    • (2013) Blood , vol.121 , pp. 489-498
    • Khorashad, J.S.1    Kelley, T.W.2    Szankasi, P.3
  • 24
    • 84887062699 scopus 로고    scopus 로고
    • Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
    • Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013;122(9):1634-48
    • (2013) Blood , vol.122 , Issue.9 , pp. 1634-1648
    • Soverini, S.1    De Benedittis, C.2    Machova Polakova, K.3
  • 25
    • 70349245253 scopus 로고    scopus 로고
    • Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in-vitro sensitivity of BCR-ABL kinase domain mutations
    • Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in-vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114: 2037-43
    • (2009) Blood , vol.114 , pp. 2037-2043
    • Jabbour, E.1    Jones, D.2    Kantarjian, H.M.3
  • 26
    • 84255197306 scopus 로고    scopus 로고
    • Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV
    • Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760-8
    • (2011) Blood , vol.118 , pp. 6760-6768
    • Fabarius, A.1    Leitner, A.2    Hochhaus, A.3
  • 27
    • 84864478365 scopus 로고    scopus 로고
    • Additional chromosome abnormalities in Philadelphia-positive clone: Adverse prognostic influene on frontline imatinib therapy: A GIMEMA Working Party on CML analysis
    • Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosome abnormalities in Philadelphia-positive clone: Adverse prognostic influene on frontline imatinib therapy: A GIMEMA Working Party on CML analysis. Blood 2012;120(4):761-7
    • (2012) Blood , vol.120 , Issue.4 , pp. 761-767
    • Luatti, S.1    Castagnetti, F.2    Marzocchi, G.3
  • 28
    • 77952845388 scopus 로고    scopus 로고
    • Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
    • Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673-81
    • (2010) Cancer , vol.116 , pp. 2673-2681
    • Verma, D.1    Kantarjian, H.2    Shan, J.3
  • 29
    • 78651337547 scopus 로고    scopus 로고
    • Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
    • Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7-22
    • (2011) Leukemia , vol.25 , pp. 7-22
    • Bixby, D.1    Talpaz, M.2
  • 30
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37
    • (2006) Blood , vol.108 , pp. 28-37
    • Hughes, T.1    Deininger, M.2    Hochhaus, A.3
  • 31
    • 54049139246 scopus 로고    scopus 로고
    • Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
    • Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112(8):3330-8
    • (2008) Blood , vol.112 , Issue.8 , pp. 3330-3338
    • Branford, S.1    Fletcher, L.2    Cross, N.C.3
  • 32
    • 70450277223 scopus 로고    scopus 로고
    • Harmonization of molecular monitoring of CML therapy in Europe
    • Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23(11):1957-63
    • (2009) Leukemia , vol.23 , Issue.11 , pp. 1957-1963
    • Müller, M.C.1    Cross, N.C.2    Erben, P.3
  • 33
    • 84867405606 scopus 로고    scopus 로고
    • Standardized definitions of molecular response in chronic myeloid leukemia
    • Cross NCP, White HE, Müller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26(10):2172-5
    • (2012) Leukemia , vol.26 , Issue.10 , pp. 2172-2175
    • Ncp, C.1    White, H.E.2    Müller, M.C.3
  • 35
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analsys
    • De Lavallade H, Apperley JF, Khorashad J, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analsys. J Clin Oncol 2008;26:3358-63
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • De Lavallade, H.1    Apperley, J.F.2    Khorashad, J.3
  • 36
    • 70350442594 scopus 로고    scopus 로고
    • High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: High rated of rapid cytogenetic and molecular responses
    • Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: high rated of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-9
    • (2009) J Clin Oncol , vol.27 , pp. 4754-4759
    • Cortes, J.E.1    Kantarjian, H.M.2    Goldberg, S.L.3
  • 37
    • 77956034332 scopus 로고    scopus 로고
    • Early intervention during imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group
    • Cervantes F, Lopez-Garrido P, Montero MI , et al. Early intervention during imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group. Haematologica 2010;95(8):1317-24
    • (2010) Haematologica , vol.95 , Issue.8 , pp. 1317-1324
    • Cervantes, F.1    Lopez-Garrido, P.2    Montero, M.I.3
  • 38
    • 79960408943 scopus 로고    scopus 로고
    • Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the czech republic and the whole of slovakia after 200 - A report from the population-based CAMELIA registry
    • Faber E, Muzik J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 200 - a report from the population-based CAMELIA registry. Eur J Haematol 2011;87:157-68
    • (2011) Eur J Haematol , vol.87 , pp. 157-168
    • Faber, E.1    Muzik, J.2    Koza, V.3
  • 39
    • 78650625238 scopus 로고    scopus 로고
    • Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
    • Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus Peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21
    • (2010) N Engl J Med , vol.363 , pp. 2511-2521
    • Preudhomme, C.1    Guilhot, J.2    Nicolini, F.E.3
  • 40
    • 79957588158 scopus 로고    scopus 로고
    • Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome a survey by the GIMEMA CML working party
    • Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML working party. Blood 2011;117(21):5591-9
    • (2011) Blood , vol.117 , Issue.21 , pp. 5591-5599
    • Gugliotta, G.1    Castagnetti, F.2    Palandri, F.3
  • 41
    • 79955018499 scopus 로고    scopus 로고
    • Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia
    • Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29: 1634-42
    • (2011) J Clin Oncol , vol.29 , pp. 1634-1642
    • Hehlmann, R.1    Lauseker, M.2    Jung-Munkwitz, S.3
  • 42
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the international randomized study of interferon and sti571 (iris)
    • Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116(19): 3758-65
    • (2010) Blood , vol.116 , Issue.19 , pp. 3758-3765
    • Hughes, T.P.1    Hochhaus, A.2    Branford, S.3
  • 43
    • 84862907694 scopus 로고    scopus 로고
    • Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    • Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30(3):232-8
    • (2012) J Clin Oncol , vol.30 , Issue.3 , pp. 232-238
    • Marin, D.1    Ibrahim, A.R.2    Lucas, C.3
  • 44
    • 84870752970 scopus 로고    scopus 로고
    • Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia
    • Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Clin Oncol 2012;30(35):4323-9
    • (2012) J Clin Oncol , vol.30 , Issue.35 , pp. 4323-4329
    • Branford, S.1    Kim, D.W.2    Soverini, S.3
  • 45
    • 84865864744 scopus 로고    scopus 로고
    • Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia
    • Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 2012;26:2096-102
    • (2012) Leukemia , Issue.26 , pp. 2096-2102
    • Hanfstein, B.1    Muller, M.C.2    Hehlmann, R.3
  • 46
    • 84864041318 scopus 로고    scopus 로고
    • Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    • Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012; 120(2):291-4
    • (2012) Blood , vol.120 , Issue.2 , pp. 291-294
    • Marin, D.1    Hedgley, C.2    Clark, R.E.3
  • 48
    • 84881289808 scopus 로고    scopus 로고
    • Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: Results with four tyrosine kinase inhibitor modalities
    • Jain P, Kantarjian HM, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: Results with four tyrosine kinase inhibitor modalities. Blood 2013; 121(24):4867-74
    • (2013) Blood , vol.121 , Issue.24 , pp. 4867-4874
    • Jain, P.1    Kantarjian, H.M.2    Nazha, A.3
  • 49
    • 84897007532 scopus 로고    scopus 로고
    • Early molecular response predict outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
    • Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predict outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123(9):1353-60
    • (2014) Blood , vol.123 , Issue.9 , pp. 1353-1360
    • Hughes, T.P.1    Saglio, G.2    Kantarjian, H.M.3
  • 50
    • 84893136765 scopus 로고    scopus 로고
    • Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial
    • Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial. Blood 2014;123:494-500
    • (2014) Blood , vol.123 , pp. 494-500
    • Jabbour, E.1    Kantarjian, H.M.2    Saglio, G.3
  • 51
    • 84878263769 scopus 로고    scopus 로고
    • Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early interventions strategies
    • Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early interventions strategies. Blood 2013;121: 2739-42
    • (2013) Blood , vol.121 , pp. 2739-2742
    • Neelakantan, P.1    Gerrard, G.2    Lucas, C.3
  • 52
    • 84863011486 scopus 로고    scopus 로고
    • Dasatinib or imatinib in newly diagnosed chronic-phase chronic. Myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (dasision)
    • Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic. myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119(5):1123-9
    • (2012) Blood , vol.119 , Issue.5 , pp. 1123-1129
    • Kantarjian, H.M.1    Shah, N.P.2    Cortes, J.E.3
  • 53
    • 84867395848 scopus 로고    scopus 로고
    • Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    • Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26(10):2197-203
    • (2012) Leukemia , vol.26 , Issue.10 , pp. 2197-2203
    • Larson, R.A.1    Hochhaus, A.2    Hughes, T.P.3
  • 54
    • 79251546724 scopus 로고    scopus 로고
    • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    • Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117(4):1141-5
    • (2011) Blood , vol.117 , Issue.4 , pp. 1141-1145
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3
  • 55
    • 84873568081 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    • Giles FJ, le Coutre PD, Pinilla-Ibartz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-12
    • (2013) Leukemia , vol.27 , pp. 107-112
    • Giles, F.J.1    Le Coutre, P.D.2    Pinilla-Ibartz, J.3
  • 56
    • 76549116248 scopus 로고    scopus 로고
    • Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
    • Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40
    • (2010) Haematologica , vol.95 , pp. 232-240
    • Shah, N.P.1    Kim, D.W.2    Kantarjian, H.3
  • 58
    • 80055070888 scopus 로고    scopus 로고
    • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia-chromosome positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    • Cortes JE, Kantarjian HM, Brummendorf TK, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia-chromosome positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118: 4567-76
    • (2011) Blood , vol.118 , pp. 4567-4576
    • Cortes, J.E.1    Kantarjian, H.M.2    Brummendorf, T.K.3
  • 59
    • 84859836481 scopus 로고    scopus 로고
    • Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    • Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-12
    • (2012) Blood , vol.119 , Issue.15 , pp. 3403-3412
    • Khoury, H.J.1    Cortes, J.E.2    Kantarjian, H.M.3
  • 60
    • 84870012939 scopus 로고    scopus 로고
    • Ponatinib in refractory chromosome-positive leukemias
    • Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory chromosome-positive leukemias. N Engl J Med 2012;367: 2075-88
    • (2012) N Engl J Med , Issue.367 , pp. 2075-2088
    • Cortes, J.E.1    Kantarjian, H.2    Shah, N.P.3
  • 61
    • 84887127701 scopus 로고    scopus 로고
    • A phase 2 trial of ponatinib in Philadelphia chromosom-positive leukemias
    • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosom-positive leukemias. N Engl J Med 2013;369(19):1783-96
    • (2013) N Engl J Med , vol.369 , Issue.19 , pp. 1783-1796
    • Cortes, J.E.1    Kim, D.W.2    Pinilla-Ibarz, J.3
  • 62
    • 84857510443 scopus 로고    scopus 로고
    • Response to second line tyrosine kinase inhibitors are durable: An intention-to-treat analysis in chronic myeloid leukemia patients
    • Milojkovic D, Apperley JF, Gerrard G, et al. Response to second line tyrosine kinase inhibitors are durable: An intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012; 119(8):1838-43
    • (2012) Blood , vol.119 , Issue.8 , pp. 1838-1843
    • Milojkovic, D.1    Apperley, J.F.2    Gerrard, G.3
  • 63
    • 50949119729 scopus 로고    scopus 로고
    • Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    • Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008;112:516-18
    • (2008) Blood , vol.112 , pp. 516-518
    • Tam, C.S.1    Kantarjian, H.2    Garcia-Manero, G.3
  • 64
    • 67149147422 scopus 로고    scopus 로고
    • Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine linase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastic phase
    • Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine linase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastic phase. Blood 2009;113:5058-63
    • (2009) Blood , vol.113 , pp. 5058-5063
    • Fava, C.1    Kantarjian, H.M.2    Jabbour, E.3
  • 65
    • 76549114789 scopus 로고    scopus 로고
    • Early prediction of success or failure of treatment with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    • Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95: 224-31
    • (2010) Haematologica , vol.95 , pp. 224-231
    • Milojkovic, D.1    Nicholson, E.2    Apperley, J.F.3
  • 66
    • 79951477784 scopus 로고    scopus 로고
    • Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    • Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011;117(6):1822-7
    • (2011) Blood , vol.117 , Issue.6 , pp. 1822-1827
    • Jabbour, E.1    Kantarjian, H.2    Obrien, S.3
  • 67
    • 84876132746 scopus 로고    scopus 로고
    • Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
    • Jabbour E, le Coutre PD, Cortes J, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 2013;27(4): 907-13
    • (2013) Leukemia , vol.27 , Issue.4 , pp. 907-913
    • Jabbour, E.1    Le Coutre, P.D.2    Cortes, J.3
  • 68
    • 34147174980 scopus 로고    scopus 로고
    • Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia
    • Picard S, Titier K, Etienne G, et al. Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9
    • (2007) Blood , vol.109 , pp. 3496-3499
    • Picard, S.1    Titier, K.2    Etienne, G.3
  • 69
    • 64049099666 scopus 로고    scopus 로고
    • Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    • Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-60
    • (2009) Blood , vol.113 , pp. 2154-2160
    • Jabbour, E.1    Kantarjian, H.M.2    Jones, D.3
  • 70
    • 70350507997 scopus 로고    scopus 로고
    • AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    • O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
    • (2009) Cancer Cell , vol.16 , pp. 401-412
    • Ohare, T.1    Shakespeare, W.C.2    Zhu, X.3
  • 71
    • 79959311524 scopus 로고    scopus 로고
    • Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008
    • Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29: 2514-20
    • (2011) J Clin Oncol , vol.29 , pp. 2514-2520
    • Bjorkholm, M.1    Ohm, L.2    Eloranta, S.3
  • 72
    • 84857731311 scopus 로고    scopus 로고
    • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience
    • Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 2012;119(9):1981-7
    • (2012) Blood , vol.119 , Issue.9 , pp. 1981-1987
    • Kantarjian, H.1    Obrien, S.2    Jabbour, E.3
  • 73
    • 41449106741 scopus 로고    scopus 로고
    • Monitoring treatment of chronic myeloid leukemia
    • Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;92:161-9
    • (2008) Haematologica , vol.92 , pp. 161-169
    • Baccarani, M.1    Pane, F.2    Saglio, G.3
  • 74
    • 79751533746 scopus 로고    scopus 로고
    • Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    • Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201-10
    • (2011) Leukemia , vol.25 , pp. 201-210
    • Jabbour, E.1    Deininger, M.2    Hochhaus, A.3
  • 75
    • 84857655242 scopus 로고    scopus 로고
    • Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
    • Rosti G, Castagnetti F, Gugliotta G, et al. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev 2012;38:241-8
    • (2012) Cancer Treat Rev , vol.38 , pp. 241-248
    • Rosti, G.1    Castagnetti, F.2    Gugliotta, G.3
  • 76
    • 84868354463 scopus 로고    scopus 로고
    • Off-target effects of BCR-ABL1 inhibitors and their potential long term implications in patients with chronic myeloid leukemia
    • Steegmann JL, Cervantes F, le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53(12):2351-62
    • (2012) Leuk Lymphoma , vol.53 , Issue.12 , pp. 2351-2362
    • Steegmann, J.L.1    Cervantes, F.2    Le Coutre, P.3
  • 77
    • 84861519200 scopus 로고    scopus 로고
    • Dasatinib inhibits proinflammatory functions of mature human neutrophils
    • Futosi K, Nemeth T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119(21):4981-91
    • (2012) Blood , vol.119 , Issue.21 , pp. 4981-4991
    • Futosi, K.1    Nemeth, T.2    Pick, R.3
  • 78
    • 84861515013 scopus 로고    scopus 로고
    • The shady side of dasatinib
    • Zarbock A. The shady side of dasatinib. Blood 2012;119(21):4817-18
    • (2012) Blood , vol.119 , Issue.21 , pp. 4817-4818
    • Zarbock, A.1
  • 79
    • 84878899268 scopus 로고    scopus 로고
    • Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib nilotinib or non-tyrosine kinase therapy: A retrospective cohort analysis
    • Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia 2013;27(6):1310-15
    • (2013) Leukemia , vol.27 , Issue.6 , pp. 1310-1315
    • Giles, F.J.1    Mauro, M.J.2    Hong, F.3
  • 80
    • 84878910858 scopus 로고    scopus 로고
    • Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
    • Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27(6):1316-21
    • (2013) Leukemia , vol.27 , Issue.6 , pp. 1316-1321
    • Kim, T.D.1    Rea, D.2    Schwarz, M.3
  • 81
    • 80055086681 scopus 로고    scopus 로고
    • Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared to the general population
    • Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared to the general population. Blood 2011; 118(17):4554-60
    • (2011) Blood , vol.118 , Issue.17 , pp. 4554-4560
    • Efficace, F.1    Baccarani, M.2    Breccia, M.3
  • 82
    • 84880278964 scopus 로고    scopus 로고
    • Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
    • Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27(7): 1511-19
    • (2013) Leukemia , vol.27 , Issue.7 , pp. 1511-1519
    • Efficace, F.1    Baccarani, M.2    Breccia, M.3
  • 83
    • 84886394855 scopus 로고    scopus 로고
    • Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
    • Williams LA, Garcia Gonzales AC, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122(5):641-7
    • (2013) Blood , vol.122 , Issue.5 , pp. 641-647
    • Williams, L.A.1    Garcia Gonzales, A.C.2    Ault, P.3
  • 84
    • 84897059542 scopus 로고    scopus 로고
    • International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24
    • Epub ahead of print
    • Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Qual Life Res 2013. [Epub ahead of print]
    • (2013) Qual Life Res
    • Efficace, F.1    Baccarani, M.2    Breccia, M.3
  • 85
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: The prospective multicentre Stop Imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: The prospective multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3
  • 86
    • 84886917643 scopus 로고    scopus 로고
    • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
    • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013;122:515-22
    • (2013) Blood , vol.122 , pp. 515-522
    • Ross, D.M.1    Branford, S.2    Seymour, J.F.3
  • 87
    • 84897573995 scopus 로고    scopus 로고
    • Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
    • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-30
    • (2014) J Clin Oncol , vol.32 , pp. 424-430
    • Rousselot, P.1    Charbonnier, A.2    Cony-Makhoul, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.